3 Companies Competing to Gain Lead in Ovarian Cancer Market Fri, 24 Nov 2017 16:24:04 +0000 Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Will New Drug Approvals Boost Novartis (NVS) Portfolio? Fri, 24 Nov 2017 13:38:01 +0000 Novartis (NVS) is facing stiff generic competition for key drugs. Nevertheless, we expect approval of new drugs to boost its portfolio.
Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Thu, 23 Nov 2017 14:00:14 +0000 The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
ETFs with exposure to AbbVie, Inc. : November 20, 2017 Mon, 20 Nov 2017 16:21:37 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AbbVie, Inc. Here are 5 ETFs with the largest exposure to ABBV-US. Comparing the performance and risk of AbbVie, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval Fri, 17 Nov 2017 14:05:02 +0000 Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
Cramer applauds Miles White, Abbott CEO Thu, 16 Nov 2017 23:54:00 +0000 Jim Cramer zoomed in on the track record of Abbott CEO Miles White, who has transformed the pharmaceutical company since he took over in 1999.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.13 (median winner: 1.53)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.